for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tianjin Tianyao Pharmaceutical Co., Ltd

600488.SS

Latest Trade

4.52CNY

Change

0.28(+6.60%)

Volume

12,021,300

Today's Range

4.24

 - 

4.53

52 Week Range

3.43

 - 

5.52

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.24
Open
4.25
Volume
12,021,300
3M AVG Volume
54.38
Today's High
4.53
Today's Low
4.24
52 Week High
5.52
52 Week Low
3.43
Shares Out (MIL)
1,091.89
Market Cap (MIL)
4,935.33
Forward P/E
--
Dividend (Yield %)
1.24

Latest Developments

More

Tianjin Tianyao Pharmaceuticals Elects Zhang Jie As Chairman

Tianjin Tianyao Pharmaceuticals says dividend payment date on June 12

Tianjin Tianyao Pharmaceuticals receives ANDA approval for new drug methylprednisolone tablets

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tianjin Tianyao Pharmaceutical Co., Ltd

Tianjin Tianyao Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the research, development and manufacturing of pharmaceutical products. The Company's primary products include corticosteroid bulk pharmaceutical chemicals (BPCs), amino acid BPCs and intermediate, such as dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinolone acetate, prednisone acetate, triamcinolone acetonide, propranolol propionate and betamethasone, among others. The Company mainly distributes its products in domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.109 Bawei Road, Hedong District

+86.22.65277565

http://www.kingyork.biz

Executive Leadership

Jian Chen

Chairman of the Board, General Manager

Shiyan Ren

Chief Financial Officer, Director

Jie Zhang

Chief Technology Officer, Executive Deputy General Manager, Director

Keting Yao

Deputy General Manager

Chunli Wang

Secretary of the Board

Key Stats

Price To Earnings (TTM)
29.73
Price To Sales (TTM)
1.85
Price To Book (MRQ)
1.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
23.97
LT Debt To Equity (MRQ)
13.37
Return on Investment (TTM)
6.89
Return on Equity (TTM)
4.51

Latest News

BRIEF-Tianjin Tianyao Pharmaceuticals to sell 3.4 pct stake in trust firm

* Says it will sell 3.4 percent stake(33.7 million shares) in trust firm in Tianjin Property Rights Exchange

BRIEF-Tianjin Tianyao Pharmaceuticals signs two API technical development commission contracts worth 3 mln yuan

* Says it and Tianjin Pharmaceuticals Research Institute Co., Ltd signs two technical development commission contracts of API glycyl-glutamine and glycyltyrosine worth 3 million yuan

BRIEF-Tianjin Tianyao Pharmaceuticals production area of API passes FDA CGMP

* Says its API production area passes U.S. FDA CGMP and gets permission to continue selling in U.S. market

BRIEF-Tianjin Tianyao Pharma's board elects chairman

Tianjin Tianyao Pharmaceuticals Co Ltd * Says board elects Chen Jian as chairman Source text in Chinese: http://bit.ly/2zHN0IV Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Tianjin Tianyao Pharma's chairman and general manager resigns due to change in job role

* Says Chairman and General Manager Wang Fujun resigns due to change in job role

BRIEF-Tianjin Tianyao's share trade to halt pending regulatory review of acquisition plan

* Says share trade to halt from Feb 16 pending regulatory review of its asset acquisition proposal

BRIEF-Tianjin Tianyao Pharma's share trade to resume after revising acquisition proposal

* Says share trade to resume on Oct 12 after revising details in its asset acquisition proposal

BRIEF-Tianjin Tianyao Pharma's shares to halt trading from Sept 28 pending announcement

* Says shares to halt trading from September 28 pending announcement related to asset restructuring

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up